Drugs / MASCT-I injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05877651 | Apr 2020 → Oct 2021 | cancer | HRYZ Biotech Co. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MASCT-I injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05877651 ↗ |
| Modality | Cell therapy | “The final products of MASCT-I technology are dendritic cells (DC) and effector T cells” NCT05877651 ↗ |